Focused On-demand Library for Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P51553

UPID:

IDH3G_HUMAN

Alternative names:

Isocitric dehydrogenase subunit gamma; NAD(+)-specific ICDH subunit gamma

Alternative UPACC:

P51553; E9PDD5; Q9BUU5

Background:

Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial, known as Isocitric dehydrogenase subunit gamma or NAD(+)-specific ICDH subunit gamma, plays a pivotal role in cellular metabolism. It is a regulatory subunit essential for the allosteric regulation of the enzyme that catalyzes the decarboxylation of isocitrate into alpha-ketoglutarate, a critical step in the citric acid cycle.

Therapeutic significance:

Understanding the role of Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial could open doors to potential therapeutic strategies.